Meiji Seika Pharma highlights Phase III nacubactam data at ESCMID Global Congress 2026

• Meiji Holdings subsidiary Meiji Seika Pharma reported Phase III Integral-2 results for nacubactam, highlighted in The Lancet Microbe at ESCMID 2026.
• Trial met prespecified objectives in carbapenem-resistant Gram-negative infections excluding Acinetobacter; no major safety concerns reported.
• Overall treatment success 7 days post-treatment: cefepime/nacubactam 44.4% (12/27); aztreonam/nacubactam 50% (12/24); BAT 26.1% (6/23).
• Japan NDA for nacubactam combinations filed in December 2025, supported by Integral-1 and Integral-2 Phase III studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Meiji Holdings Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607162100BIZWIRE_USPR_____20260716_BW351188) on July 17, 2026, and is solely responsible for the information contained therein.